Akero Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology firm, has announced its participation in the 39th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2021, at 10:50 a.m. EST. Investors can view the live webcast through the company's website, with an archived version available for 30 days post-event.

Akero is focused on developing innovative treatments for non-alcoholic steatohepatitis (NASH) and metabolic disorders. Its lead drug candidate, Efruxifermin (EFX), is undergoing a Phase 2a clinical trial.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will present virtually at the 39^th Annual J.P. Morgan Healthcare Conference at 10:50 a.m. EST on Tuesday, January 12, 2021.

A live webcast of the presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website for 30 days.

About Akero Therapeutics

Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance to improve overall health. The company’s lead product candidate, Efruxifermin (EFX), formerly known as AKR-001, is currently being evaluated in an ongoing Phase 2a clinical trial. Akero Therapeutics is headquartered in South San Francisco, CA. For more information, please visit www.akerotx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005739/en/

FAQ

When will Akero Therapeutics present at the J.P. Morgan Healthcare Conference?

Akero Therapeutics will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 10:50 a.m. EST.

Where can I watch the Akero Therapeutics presentation?

The presentation can be viewed live on Akero Therapeutics' investor relations section of their website.

What is the focus of Akero Therapeutics?

Akero Therapeutics focuses on developing treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders.

What is the lead product candidate of Akero Therapeutics?

The lead product candidate is Efruxifermin (EFX), currently in a Phase 2a clinical trial.

How long will the Akero presentation be available online?

An archived replay of the Akero presentation will be available on their website for 30 days after the event.